Abstract

The purpose of publishing the resolution of the Interdisciplinary Council of Experts in the fields of pulmonology, allergology, pediatrics, and clinical pharmacology was to discuss the effectiveness and safety of a new short-acting β 2 -adrenergic receptor agonist in the Russian Federation – levosalbutamol. The Interdisciplinary Council of Experts in the fields of pulmonology, allergology, pediatrics, and clinical pharmacology took place on March 19, 2024 in Moscow. Results. According to the research results, the following advantages of using levosalbutamol have been demonstrated: the affinity for β 2 -adrenergic receptors is 2 times higher compared to salbutamol; the drug affects the sensitization of β 2 receptors to a lesser degree; levosalbutamol does not cause increased airway hyperresponsiveness; levosalbutamol has a more pronounced anti-inflammatory effect; greater safety for the cardiovascular system was noted. Conclusion. According to the presented data, the inclusion of levosalbutamol in clinical guidelines for asthma (age category “children, adults”) and chronic obstructive pulmonary disease (age category “adults”) is justified.